eligibility_summary
Adults 18–70 post-allogeneic HSCT with persistent CMV/EBV despite standard therapy, on ≤0.5 mg/kg/day prednisone, ECOG ≤3, SpO2 ≥90% on room air, expected survival >3 months, multi-virus CTLs available, negative pregnancy test if applicable, consent required. Exclude: <28 days post-HSCT, grade III–IV aGVHD or ≥moderate cGVHD, severe organ dysfunction, recent (≤28 days) DLI/CTL/CAR-T/NK/T-cell mAbs/other trials, poor compliance or deemed unsuitable.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
manual_review_required
ai_summary
Intervention: Partial HLA‑matched multivirus-specific T cells (VSTs) directed against CMV and EBV, a biologic, adoptive cellular immunotherapy (virus-specific cytotoxic T lymphocytes). Dosing: IV infusion at 1×10^7, 2×10^7, or 5×10^7 cells/m2 (phase I dose escalation, then expansion). Mechanism of action: HLA-restricted TCR recognition of CMV/EBV viral peptides on infected cells, in vivo expansion/persistence, cytokine release, and perforin/granzyme-mediated cytolysis to restore antiviral cellular immunity and clear refractory infection after allo-HSCT. Targets: CMV- and EBV-infected cells (notably EBV-infected B cells post-transplant). Pathways engaged: antigen presentation via HLA, TCR signaling, and cytotoxic T-cell effector pathways.